Every material Form 8-K Ashland Global filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Ashland reported preliminary fourth-quarter fiscal 2026 sales of $498 million, up 4% from the prior-year quarter, and adjusted EBITDA of $121 million, up 2%. GAAP results were weaker: a net loss of $16 million compared with net income of $32 million a year earlier. The company also issued fiscal 2027 guidance of $1,905 million to $1,975 million in sales and $405 million to $435 million in adjusted EBITDA.
Q4 sales were $498 million, up 4%; sales volumes rose 3% and pricing rose 2%.
Net loss was $16 million, or ($0.35) per diluted share; adjusted diluted EPS was $1.12 versus $1.08 a year earlier.
Specialty Additives adjusted EBITDA fell 31% to $20 million, while Life Sciences adjusted EBITDA rose 16% to $64 million.
Fiscal 2027 guidance: sales of $1,905 million to $1,975 million and adjusted EBITDA of $405 million to $435 million; fiscal 2026 adjusted EBITDA was $385 million.
Ashland amended and restated its existing European accounts receivable securitization program, with a facility limit of €125 million, extending the scheduled termination date to September 21, 2029. Bank of America, N.A. continues as administrative and structuring agent, and its committed purchaser role moved to Bank of America Europe DAC. The filing describes the changes as routine market-standard updates, and it discloses no change to the facility limit.
Agreement dated September 24, 2026 amends the EU A/R Facility originally set up under documents dated October 19, 2023
Scheduled termination date extended to September 21, 2029
Aggregate facility limit of €125 million is unchanged in the filing
Bank of America Europe DAC replaces Bank of America, N.A. as committed purchaser
Ashland Inc. entered into a Fifth Amendment to its Receivables Purchase Agreement with PNC Bank on July 30, 2026. The amendment keeps commitments of up to $70 million and extends the facility's termination date from September 11, 2026 to July 28, 2028. The filing describes this as a routine update to a financing arrangement, with no change to the commitment amount.
Commitments under the accounts receivable securitization facility remain up to $70 million.
The RPA termination date moves from September 11, 2026 to July 28, 2028.
The amendment is dated July 30, 2026, and PNC Bank, National Association is administrative agent.
The filing says the amendment makes other updates consistent with current market standards, without giving details.
Ashland Inc. appointed Peter Thomas and Allen Spizzo as independent directors on July 27, 2026, and entered into a Cooperation Agreement with stockholder Ancora Holdings Group, LLC. The company also formed a Capital Allocation Advisory Committee to make recommendations to the Board on capital allocation strategy. The filing does not include financial results, so it gives shareholders governance changes rather than a measure of operating performance.
Peter Thomas and Allen Spizzo appointed as independent directors effective July 27, 2026; Board temporarily expands to 11 members, then reduces to 10 at the 2027 Annual Meeting
Cooperation Agreement with Ancora includes voting commitments and standstill obligations, and remains in effect through a Standstill Period tied to the 2028 Annual Meeting notice deadline
Capital Allocation Advisory Committee chaired by Scott A. Tozier, with Thomas as Vice Chair and Guillermo Novo as non-voting member
Ashland reported preliminary third-quarter fiscal 2026 results, with sales up 7% to $497 million on higher volumes across all business units, while Adjusted EBITDA fell 4% to $109 million. The company reaffirmed its full-year sales and Adjusted EBITDA guidance but revised its adjusted EPS outlook to low-to-mid single-digit growth from mid-to-high single-digit growth, citing a higher tax rate.
Q3 sales of $497 million, up from $463 million; sales volumes rose 6%
Adjusted EBITDA of $109 million, down from $113 million, with a 21.9% margin
Income from continuing operations of $41 million, or $0.89 per diluted share, versus a loss of $719 million a year earlier, which included a $706 million goodwill impairment
Adjusted EPS outlook cut to low-to-mid single-digit growth from mid-to-high single-digit growth; sales ($1,835-$1,870 million) and Adjusted EBITDA ($385-$400 million) guidance reaffirmed
Ashland Inc. signed a Second Amended and Restated Credit Agreement on May 28, 2026, providing a $500 million five-year unsecured revolving credit facility that the company and its Swiss subsidiary can draw on for working capital and general corporate purposes. The filing says the agreement amends and restates Ashland's July 22, 2022 credit agreement, and it sets the initial borrowing spread and commitment fee at levels that move with the company's leverage ratio.
Revolving facility of $500 million over five years, including a $125 million letter of credit sublimit
Initial interest margin of Term SOFR or EURIBOR plus 1.375%, moving between 1.250% and 1.750% based on the Consolidated Net Leverage Ratio
Initial unused commitment fee of 0.175% per annum, moving between 0.125% and 0.275%
Agreement replaces the Amended and Restated Credit Agreement dated July 22, 2022; facility may be prepaid without premium
Ashland Inc. increased its board from eight to nine directors and appointed Bertrand Loy as an independent director effective May 15, 2026. Loy also joins the Audit Committee and the Governance and Nominating Committee, and the company said the expansion anticipates potential director retirements under its board policy.
Bertrand Loy appointed independent director effective May 15, 2026; board size raised from eight to nine
Loy named to the Audit Committee and the Governance and Nominating Committee, effective May 15, 2026
Loy receives a prorated annual restricted stock unit grant until the next annual award in January 2027
Loy is currently executive chair of Entegris Inc. and previously served as its president and chief executive officer
Ashland reported second-quarter fiscal 2026 sales of $482 million, up one percent, but Adjusted EBITDA fell nine percent to $98 million and net income dropped to $16 million from $31 million. The company updated its full-year fiscal 2026 guidance to sales of $1,835 million to $1,870 million and Adjusted EBITDA of $385 million to $400 million, citing a slower-than-expected productivity ramp at its Hopewell facility.
Q2 sales $482 million, up one percent; pricing declined two percent
Q2 Adjusted EBITDA $98 million, down nine percent from $108 million; net income $16 million vs. $31 million
Full-year fiscal 2026 Adjusted EBITDA guidance $385 million to $400 million; sales guidance $1,835 million to $1,870 million
Fiscal 2026 manufacturing optimization savings expectations reduced by approximately $10 million to $12 million
Ashland reported first-quarter fiscal 2026 sales of $386 million, down 5% from $405 million a year earlier, and Adjusted EBITDA of $58 million, down 5%. The company narrowed its full-year Adjusted EBITDA guidance to $400 million to $420 million from $400 million to $430 million, citing about $11 million of temporary impacts from the Calvert City startup delay and weather disruptions, isolated to the second quarter.
Sales $386 million, down 5% from $405 million; Adjusted EBITDA $58 million, down 5% from $61 million
Net loss of $12 million, or $(0.26) per diluted share, versus a $165 million loss a year earlier that included the Avoca impairment
Fiscal 2026 Adjusted EBITDA guidance narrowed to $400 million to $420 million from $400 million to $430 million
Calvert City startup delay and recent weather disruptions cited for approximately $11 million of temporary impacts in the second quarter
Ashland's Compensation Committee approved a one-time equity award of $2,000,000 in restricted stock units to Chair and CEO Guillermo Novo, under a letter agreement dated January 26, 2026. The units cliff-vest on December 31, 2028, and are meant to encourage his continued employment through at least that date.
Award value is $2,000,000, allocated 100% to time-based restricted stock units
Units cliff-vest on December 31, 2028, subject to Novo's continued employment
Grant date is two business days after the Form 10-Q for first quarter fiscal 2026 is released
Novo waived accelerated vesting on retirement before December 31, 2028 and agreed to 180 days' notice of resignation
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Ashland Global filing is on SEC EDGAR ↗. 8-K briefs of other companies →